Global Gene Therapy Partnering Terms and Agreements 2014 to 2020

$3,495.00

The Global Gene Therapy Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2020
Number of pages
250+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP2115

The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in gene therapy partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Gene therapypartnering contract documents
  • Top gene therapy deals by value

 

The Global Gene Therapy Partnering Terms and Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

 

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.  

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

 

The initial chapters of this report provide an orientation of Gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Gene therapy dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Gene therapy deals since 2014. Deals are listed by headline value, signed by big pharma, most active Gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Gene therapy dealmaking with a brief summary followed by a comprehensive listing of Gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan 2014. The chapter is organized by specific Gene therapy technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gene therapy technologies and products.

 

Report scope

 

Global Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.

 

Global Gene Therapy Partnering Terms and Agreements includes:

 

  • Trends in gene therapy dealmaking in the biopharma industry since 2014
  • Analysis of gene therapy deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life gene therapy deals
  • Access to over 340 gene therapy deals
  • The leading gene therapy deals by value since 2014
  • Most active gene therapy dealmakers since 2014
  • The leading gene therapy partnering resources

 

 In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Global Gene Therapy Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of gene therapy deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of gene therapy agreements with numerous real life case studies
  • Comprehensive access to over 340 actual gene therapy deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of  gene therapy deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading gene therapy deals by value since 2014
  • Identify the most active gene therapy dealmakers since 2014
  • Detailed access to actual gene therapy contracts enter into by the leading bigpharma
  • Insight into the terms included in gene therapy agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Gene therapy dealmaking

 

2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Most active Gene therapy dealmakers
2.4. Gene therapy partnering by deal type
2.5. Gene therapy partnering by therapy area
2.6. Deal terms for Gene therapy partnering
2.6.1 Gene therapy partnering headline values
2.6.2 Gene therapy deal upfront payments
2.6.3 Gene therapy deal milestone payments
2.6.4 Gene therapy royalty rates

 

Chapter 3 – Leading Gene therapy deals

 

3.1. Introduction
3.2. Top Gene therapy deals by value

 

Chapter 4 – Most active Gene therapy dealmakers

 

4.1. Introduction
4.2. Most active Gene therapy dealmakers
4.3. Most active Gene therapy partnering company profiles

 

Chapter 5 – Gene therapy contracts dealmaking directory

 

5.1. Introduction
5.2. Gene therapy contracts dealmaking directory

 

Chapter 6 – Gene therapy dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Gene therapy deals by company A-Z

 

Appendix 2 – Gene therapy deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Gene therapy deals by deal type

 

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

 

Appendix 4 – Gene therapy deals by therapy area

 

Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

 

Appendix 5 –Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Gene therapy partnering since 2014
Figure 2: Active Gene therapy dealmaking activity since 2014
Figure 3: Gene therapy partnering by deal type since 2014
Figure 4: Gene therapy partnering by disease type since 2014
Figure 5: Gene therapy deals with a headline value
Figure 6: Gene therapy deals with an upfront value
Figure 7: Gene therapy deals with a milestone value
Figure 8: Gene therapy deals with a royalty rate value
Figure 9: Top Gene therapy deals by value since 2014
Figure 10: Most active Gene therapy dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Molecular Therapeutics, AAVLife, Abby Grace Foundation, Abeona Therapeutics, Ablynx, Accenture, Actinium Pharmaceuticals, Addex Therapeutics, Advanced BioScience Laboratories, Advanced Biotherapeutics Consulting, Aevitas Therapeutics, Affinia Therapeutics, AffyXell Therapeutics, Agensys, Agilis Biotherapeutics, Agrivida, AGTC, Akouos, Alcyone Lifesciences, Alder Biopharmaceuticals, Aldevron, Allergan, Alliance for Cancer Gene Therapy, Alliance for Regenerative Medicine, Allogene Therapeutics, Alnylam Pharmaceuticals, ALS Finding a Cure Foundation, Amarna Therapeutics, Ambys Medicines, American Association of Neuromuscular & Electrodiagnostic Medicine, American Gene Technologies, Amicus Therapeutics, AmorChem, Angionetics, Annapurna Therapeutics, Applied DNA Sciences, Applied StemCell, Arbor Biotechnologies, Aruvant Sciences, Ascenion, ASC Therapeutics, Asklepios Biopharmaceutical, Astellas Pharma, Auburn University, Audentes Therapeutics, Avacta, Avalanche Biotechnologies, Avectas, Avellino Labs, AveXis, Avita Medical, Avrobio, Avvinity Therapeutics, Axovant Sciences, Axxam, Bayer, B Braun, B Braun CeGaT, Beam Therapeutics, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Benitec Biopharma, Be The Match BioTherapies, BIA Separations, Bill and Melinda Gates Foundation, Bio-Techne, BioCure, Biogen, BioMarin Pharmaceutical, Bionic Sight, Biotechnology and Biological Sciences Research Council (BBSRC), Bioverativ, Blackstone, Blood Centers of America, Blood Systems Research Institute, Bluebird Bio, Boehringer Ingelheim, Bpifrance, Brammer Bio, BridgeBio Pharma, Bristol-Myers Squibb, Broad Institute, Butantan Institute, California Institute for Regenerative Medicine, Calimmune, CAMP4 Therapeutics, Casebia Therapeutics, Case Western Reserve University, Castle Creek Pharmaceuticals, Catalent, Cedars-Sinai Health System, CeGaT, Celgene, Celladon, Cell and Gene Therapy Catapult, Cellectis Bioresearch, Celtic Biotech, Centauri Therapeutics, Center for Biomarker Research in Medicine, Cevec Pharmaceuticals, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Hospital of Pittsburgh, Children's Medical Research Institute, Children's Research Institute, Cincinnati Children’s Hospital Medical Center, City of Hope, ClearPoint Neuro, Clearside Biomedical, Cobra Biologics, Codexis, Cognate BioServices, Columbia University, CombiGene, Copernicus Therapeutics, CPI International, CRISPR Therapeutics, CryoPort, CSL Behring, Cyprium Therapeutics, Cystic Fibrosis Foundation, Cytoo, Daewoong Pharmaceutical, Deloitte, Denovo Biopharma, Dimension Therapeutics, DiNAQOR, DNA Script, Dr. Reddy's Laboratories, Duke University, Dyno Therapeutics, Editas Medicine, Eiger BioPharmaceuticals, ElevateBio, enGene, Enterprise Partners Venture Capital, Eunice Kennedy Shriver Institute of Child Health and Human Development, European Union, Eversana, Evotec, Expression Therapeutics, Fate Therapeutics, Federal Ministry of Education and Research (BMBF), FerGene, Ferring Pharmaceuticals, Fibrocell Science, FIT Biotech, Five Prime Therapeutics, FKD Therapies, FloDesign Sonics, Fondazione San Raffaele, Fondazione Telethon, Fortress Biotech, Forty Seven, Foundation Fighting Blindness, Foundation Medicine, Fresenius Kabi Pharmaceuticals, Friedreichs Ataxia Research Alliance, Fujifilm Diosynth Biotechnologies, GE Healthcare, Genable Technologies, GenEdit, Generation Biotech, Gene Therapy Research Institution, Genethon, Genetic Information Research Institute, genOway, Genprex, GenScript USA, GenStem Therapeutics, Genzyme, George Washington University, GeoVax, GlaxoSmithKline, GlycoBac, Great Ormond Street Hospital (GOSH), Harvard Medical School, Harvard University, HekaBio, Helmholtz Zentrum Munchen, Horama, Horizon 2020, Horizon Discovery, Hoth Therapeutics, HTG Molecular Diagnostics, Huapont Pharma, Humanigen, Icahn School of Medicine at Mount Sinai, Imperial Innovations, Innovate UK, Institute of Child Health, Institut Pasteur, International Duchenne Alliance, Intrexon, Invitae, Ion Channel Innovations, ISIS Innovation, Israeli National Authority for Technological Innovation, Iveric Bio, Janssen Biotech, Janssen Pharmaceuticals, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, Juno Therapeutics, Juventas Therapeutics, Kadmon Pharmaceuticals, Kangmei Pharma, Kite Pharma, Kogenix, Lacerta Therapeutics, Leiden University, Lentigen, LineaRx, Locana, LogicBio Therapeutics, Lonza, Lund University, Lysogene, Marken, Maryland Stem Cell Research Fund, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Max-Delbruck Center for Molecular Medicine, Maxcyte, Mayo Clinic, McKesson, MD Anderson Cancer Center, MDA Venture Philanthropy, Medac, Medgenics, Medifocus, MediGene, MedImmune, Medison Pharma, MeiraGTx, Merck and Co, Merck Serono, Microsoft, MilliporeSigma, Milo Biotechnology, Miltenyi Biotec, Morphogenesis, Muscular Dystrophy Association, Mustang Bio, Myonexus Therapeutics, NanoString Technologies, National Center for Advancing Translational Sciences (NCATS), National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Standards and Technology, National Institutes of Health, National Taiwan University Hospital, National University of Ireland, Galway (NUI Galway), Nationwide Children’s Hospital, Neurocrine Biosciences, New Jersey Innovation Institute, Nightstar Therapeutics, NightstaRx, North Carolina State University, Northern Biomedical Research, Northwestern University, Novartis, Novasep, Novo Nordisk, Ocugen, Odylia Therapeutics, Ohio State University, Oncolys BioPharma, OncoSec Medical, Ophthotech, Orchard Therapeutics, Oregon Health Sciences University, Oregon National Primate Research Center, Orgenesis, Oxford BioMedica, Oxgene, PACA Inovation, Pall Corporation, Panion, Paragon Bioservices, Parent Project Muscular Dystrophy, Passage Bio, Paul Ehrlich Institute, PCT, Perelman School of Medicine, Pfizer, PharmaCell, PlantArcBio, PlasmaTech Biopharmaceuticals, PlasmidFactory, Plasticell, Population Diagnostics, Precision BioSciences, Prevail Therapeutics, PreveCeutical Medical, Prime Medicine, Provecs Medical, PsiOxus Therapeutics, PTC Therapeutics, Regeneron Pharmaceuticals, Regenxbio, ReGenX Biosciences, ReNeuron, Renova Therapeutics, Renovo, Research Development Foundation, RetroSense Therapeutics, Roche, Rocket Pharmaceuticals, Roivant Sciences, SAFC, Sangamo BioSciences, Sanofi, San Raffaele Telethon Institute for Gene Therapy, Santen Pharmaceutical, Santhera Pharmaceuticals, Sapreme Technologies, Sarepta Therapeutics, SAVSU Technologies, Schepens Eye Research Institute, Scottish Enterprise, Seelos Therapeutics, Selecta Biosciences, Sensorion, Shenzhen Yuanxing Bio-Pharm Science & Technology, Sirion Biotech, SiSaf, Solid Biosciences, Spark Therapeutics, Spooner Girls Foundation, SpringWorks Therapeutics, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, St Jude Medical, StrideBio, Synpromics, Synthego, T-TOP Clinical Research, Takeda Pharmaceutical, Talee Bio, Tamid Bio, TapImmune, Target ALS Foundation, Taxus Cardium Pharmaceuticals, Taysha Gene Therapies, Team Sanfilippo, Teva Pharmaceutical Industries, The Cell and Gene Therapy Unit, The Cyprus Institute of Neurology and Genetics, The Parker Institute For Cancer Immunotherapy, Theracell, Theragene Pharmaceuticals, Theravectys, Thermo Fisher Scientific, Tianjin CanSino Biotechnology, TissueGene, Tocagen, Touchlight, Trakcel, Transposagen Biopharmaceuticals, Treeway, TxCell, UK Cystic Fibrosis Gene Therapy Consortium, Ulster University, Ultragenyx Pharmaceuticals, UNeMed, UniQuest, UniQure, United Cargo, Universite Laval, University College London, University of Alabama, University of Barcelona, University of Basel, University of California, Davis, University of California, San Diego, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Colorado, University of Copenhagen, University of Eastern Finland, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Iowa, University of Kentucky, University of Leeds, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Missouri, University of Nebraska, University of North Carolina, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Pittsburgh Medical Center, University of Quebec, University of Rome, University of South Florida, University of Texas Southwestern Medical Center, University of Washington, University of Wisconsin-Madison, Urovant Sciences, Vaccine and Gene Therapy Institute of Florida (VGTI-FL), VBL Therapeutics (dba), Vertex Pharmaceuticals, Vigene Biosciences, Vineti, Vir Biotechnology, Virginia Catalyst, Vivet Therapeutics, Voyager Therapeutics, Vycellix, Weill Cornell Medical College, Wellcome Trust, Wellcome Trust Sanger Institute, Werum IT Solutions, Wilson Wolf, WIRB-Copernicus Group, Wize Pharma, Wuxi Apptec Laboratory Services, Y-Biologics, Yposkesi, Ziopharm Oncology

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.